News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Vetigenics Raises $10 Million for Pet Cancer Treatment Trials
The company will use the funds to further advance its lead cancer therapies for dogs and cats through pivotal clinical trials.
Agni Semiconductor Receives $5 Million Strategic Investment
Agni is developing a high speed, low power, multi-bit non-volatile memory based on Penn technology.
NextUP Program Provides Impact Grant Funding for Promising Pre-commercial Penn Ideas and Technologies
Applicants must include a Penn faculty member as a lead participant and an invention disclosure must be submitted to PCI.
Ascidian Therapeutics and Eli Lilly Establish Global Research Partnership
Ascidian was founded with technology developed by Jean Bennett, MD, PhD.
Exyn Technologies Completes a Successful IPO
Exyn raised $19.4 million in an initial public stock offering in May.
Meet the Penn I-Corps Spring 2026 Teams
The Spring 2026 teams have completed the Penn I-Corps program.
Craig Gravitz, JD, Joins PCI as Executive Director of PCI Ventures
Gravitz joins PCI from the Advanced Research Projects Agency for Health (ARPA‑H).
Penn Scientist Elected President of Leading Cancer Organization
In this role, he aims to advance innovation in cancer treatment and prevention.
Penn Vet Researchers Target Tumor-Supporting Cells to Advance CAR T Treatment in Pancreatic Cancer
This approach may pave the way for potentially safer, more accessible, and cost-effective treatments for solid tumors.
Mitchell Lab Engineers LNPs to Enhance mRNA Vaccine Efficacy, Reduce Side Effects
Mitchell and his team discovered that lipid nanoparticles (LNPs) can be used to modify the metabolism of immune cells.